Last reviewed · How we verify
Bitoscanat (BITOSCANATE)
Bitoscanat (generic name: BITOSCANATE) is a drug. It is currently in Phase 2 development.
Bitoscanate works by binding to specific biological molecules to produce a therapeutic effect.
Bitoscanate is a small molecule with the synonyms BITOSCANATE, BITOSCANATO, NSC-758884, and P-PHENYLENE BIS(ISOTHIOCYANATE).
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BITOSCANATE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like a city with many different buildings. Bitoscanate is like a key that fits into a specific lock on one of those buildings, allowing it to work properly and helping to treat a particular condition. However, the exact lock and building it targets are still unknown.
Approved indications
Common side effects
Key clinical trials
- Graded Motor Imagery Training in Shoulder Impingement Syndrome (NA)
- Effects of Two Techniques of Mobilization in the Dorsiflexion on Patients With Chronic Ankle Instability (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bitoscanat CI brief — competitive landscape report
- Bitoscanat updates RSS · CI watch RSS
Frequently asked questions about Bitoscanat
What is Bitoscanat?
How does Bitoscanat work?
What is the generic name of Bitoscanat?
What development phase is Bitoscanat in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing